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Abstract
Cancer stem cells (CSCs) niche in the tumor microenvironment is responsible for cancer recurrence and therapy failure.
To better understand its molecular and biological involvement in hepatocellular carcinoma (HCC) progression, one can
design more effective therapies and tailored then to individual patients. While sorafenib is currently the only approved
drug for first-line treatment of advanced stage HCC, its role in modulating the CSC niche is estimated to be small. By
contrast, transforming growth factor (TGF)-β pathway seems to influence the CSC and thus may impact hallmarks of
HCC, such as liver fibrosis, cirrhosis, and tumor progression. Therefore, blocking this pathway may offer an appealing
and druggable target. In our study, we have used galunisertib (LY2157299), a selective ATP-mimetic inhibitor of TGF-β
receptor I (TGFβI/ALK5) activation, currently under clinical investigation in HCC patients. Because the drug resistance is
mainly mediated by CSCs, we tested the effects of galunisertib on stemness phenotype in HCC cells to determine
whether TGF-β signaling modulates CSC niche and drug resistance. Galunisertib modulated the expression of
stemness-related genes only in the invasive (HLE and HLF) HCC cells inducing a decreased expression of CD44 and
THY1. Furthermore, galunisertib also reduced the stemness-related functions of invasive HCC cells decreasing the
formation of colonies, liver spheroids and invasive growth ability. Interestingly, CD44 loss of function mimicked the
galunisertib effects on HCC stemness-related functions. Galunisertib treatment also reduced the expression of
stemness-related genes in ex vivo human HCC specimens. Our observations are the first evidence that galunisertib
effectiveness overcomes stemness-derived aggressiveness via decreased expression CD44 and THY1.
Introduction
Hepatocellular carcinoma (HCC) is the most common
form of primary liver cancer. It is the fifth most common
cancer globally and the third most common cause of
cancer-related deaths1. HCC is a complex ailment asso-
ciated with numerous risk factors, thus making it difficult
to treat. Patients with underlying cirrhosis or chronic liver
diseases are at a high risk of developing HCC. Since
symptoms defining HCC are usually absent, patients
typically manifest the symptoms of cirrhotic liver
patients2. Various insults to liver such as exposure to the
toxic substances (aflatoxins), infection with hepatitis B/C
viruses, or abusive use of alcohol elicit the immune
response in the liver, which results in the inflammation
via the activation of Kupffer cells and hepatic stellate cells
and could also result in necrosis3. During this time, dif-
ferent factors, particularly transforming growth factor
(TGF)-β4,5 are involved in inducing the wound-healing
response. Mutations or alterations in this controlled
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mechanism could lead to the formation of fibrosis and
later on cirrhosis6. Cirrhosis is the advanced stage of
fibrosis and is characterized by the distortion of the liver
parenchyma associated with septate and nodule forma-
tion, altered blood flow, and risk of failure7.
Furthermore, tissue microenvironment plays a major
role in this process of HCC8,9. Interaction of a variety of
cell types in the tumor stroma with extracellular matrix
components leads to the attainment of an abnormal
phenotype that promotes tumor formation. Hypoxia
enhances progression and metastasis of HCC. Activation
of epithelial–mesenchymal transition (EMT), oxidative
stress, and inflammation also play major roles in tumor
progression10. Furthermore, cells with ‘stem-like’ features,
termed cancer stem cells (CSCs), are also present in the
liver during HCC that promotes tumor growth11. Indeed,
a better understanding of the cell types involved in the
initiation and progression of liver cancer may help to
better understand molecular mechanisms of carcinogen-
esis and therapeutic options.
TGF-β is a multifunctional cytokine that controls pro-
liferation, cellular differentiation, adhesion, migration,
apoptosis and other functions in most cells12. TGF-β acts
as a tumor suppressor in normal tissues, but once tumor
cells acquire mechanisms to overcome its suppressor
effects, it causes tumor progression13. The switch from
tumor suppressor to oncogenic is not well understood yet,
but intrinsic and extrinsic factors seem to play important
roles. The loss of cell polarity, acquisition of motile
properties, and a mesenchymal phenotype during EMT
are considered critical intrinsic changes of the tumor
cells14. A pro-tumorigenic potential of TGF-β signaling is
also mediated by extrinsic factors originating from the
tumor microenvironment, such as angiogenesis, inflam-
mation, and fibroblast activation. In addition to changes
in the tumor tissue, modifications in the TGF-β signaling
pathway can also contribute to tumor growth. Hence,
TGF-β plays a vital role in the molecular pathogenesis of
HCC; TGF-β targeting could provide new insights in the
clinical setting4. Several small-molecule inhibitors of
TGF-β receptor I/II (TGFβRI/II/ALK5) have been devel-
oped, of which three are currently in clinical develop-
ment15. Galunisertib (LY2157299), a selective ATP-
mimetic inhibitor of TGFβRI/ALK5, is the only TGF-β
pathway inhibitor currently under clinical investigation in
HCC patients (NCT01246986). Recently, galunisertib
has been shown to efficiently inhibit the expression of
p-Smad2 as well as invasion, but not proliferation, in three
HCC models in vitro16.
Keeping this in mind, here we aimed to use galunisertib
to understand its role in modulating the expression of
stemness-related genes and its effect on the clonogenicity,
spheroid formation, and invasiveness of HCC. This work
was designed to help develop a strategy on how to best
select patients for drugs that have been implicated to alter
the CSC niche or its associated biology.
Results
Invasive and non-invasive HCC cells express a different
stemness-related gene profile
Basal mRNA expression level of epithelial cell adhesion
molecule (EPCAM), CD44, THY1 (also known as CD90),
alanyl aminopeptidase membrane (ANPEP, also known as
CD13), Keratin 19 (KRT19), and prominin-1 (PROM1,
Fig. 1 Invasive and non-invasive HCC cells show a distinctive expression pattern for stemness-related markers. a Relative expression of
indicated stemness-related genes analyzed by qRT-PCR. Differences in the expression between non-invasive (white bars) and invasive (black bars)
HCC cells were highly significant (P < 0.001) for all stemness-related genes and P < 0.005 for PROM1. b Flow cytometry analyses of indicated
stemness-related proteins expressed on the cell surface. Results are expressed as % of positive cells. Mean ± SEM (N at least 3)
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also known as CD133) was quantified in seven different
HCC cell lines. Two different phenotypes of HCC cells
were distinguished as non-invasive (also epithelial, namely
HepG2, PLC/PRF/5, and Hep3B) and invasive (also
mesenchymal, HLE, HLF, SK-HEP-1, and SNU449). The
different phenotype of cells determines also differences in
stemness-related gene profile. Non-invasive HCC cells
expressed EPCAM, ANPEP, KRT19, and PROM1, whereas
invasive HCC cells expressed more mesenchymal markers
such as CD44 and THY1 (Fig. 1a). Differences in the
expression of EPCAM, CD44, THY1, ANPEP, KRT19, and
PROM1 between non-invasive and invasive HCC cells
were highly significant (P < 0.001 for all stemness-related
genes and P < 0.005 for PROM1). Flow cytometry analyses
confirmed the differential transcriptional pattern between
the two groups of cells (Fig. 1b). The cell surface
stemness-related EPCAM, ANPEP, and PROM1 were
prevalent in non-invasive cells, along with the internal
stemness-related KRT19, while CD44 and THY1 are
dominant in the invasive HCC cells (Fig. 1b).
Galunisertib modulates the stemness-gene profile of
invasive HCC cells
To test the hypothesis that galunisertib-mediated
blocking of TGFβRI affects stemness-gene profiles of
invasive HCC cells, we challenged them with galunisertib.
A long-term treatment with galunisertib significantly
reduced the expression of CD44 and THY1 in HLE and
HLF invasive cells (Fig. 2a). Furthermore, flow cytometry
analyses confirmed that galunisertib treatment notably
shifted the mean fluorescence index of CD44 and THY1
as compared to untreated cells (Fig. 2b). Altogether, data
indicate that effective inhibition of TGFβRI by galuni-
sertib reduces the stemness-gene profile of invasive HCC
cells, thus also demonstrating the potential role of TGF-β
in regulating the stemness of HCC. To reinforce the
hypothesis that the TGF-β pathway regulates stemness-
related gene expression in HCC cells, we targeted to
knockdown the TGFβRI with specific short hairpin RNA
(shRNA) in the invasive HCC cells. Down-regulation of
TGFβRI induced acquisition of a more epithelial-like
morphology in HLE and HLF cells (Supplementary Fig-
ure 1A). Efficiency in the reduction of CD44 expression
following its targeting knockdown was analyzed by flow
cytometry: presence of TGFβRI on the plasma membrane
(purple peaks in Supplementary Figure 1B), compared to
cells transfected with an unspecific shRNA (sh-: blue
peaks) and unstained cells used as an internal control
(Blank: black peaks). Western blots also demonstrated the
decrease in TGFβRI levels, which correlated with strong
inhibition in the signaling, analyzed as SMAD2 phos-
phorylation (Supplementary Fig. 1C). Interestingly, we
observed that targeting knockdown of TGFβRI exerted
similar effects as galunisertib treatment on decreasing the
expression levels of CD44, analyzed by real-time PCR
(Fig. 3a) or flow cytometry (Fig. 3b).
Galunisertib reduces clonogenicity and liver spheroid
formation ability of HCC invasive cells
To investigate the effects of the galunisertib regulation
on stemness-gene expression in terms of functionality, we
measured the clonogenic capacity (the ability of single
Fig. 2 Galunisertib modulates the stemness-gene profile of invasive HCC cells. a Relative expression of CD44 and THY1 by qRT-PCR. b Flow
cytometry analysis of CD44 and THY1 expressed on the cell surface. Results are expressed as MFI. Mean ± SEM (N at least 3). *P < 0.05; **P < 0.001
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cells to undergo unlimited division and to form colonies)
and the liver spheroid formation in HLE and HLF cells
after galunisertib treatment (Fig. 4). Consistently with our
previously described results, galunisertib reduced the
formation of colonies at various cell densities, the per-
centage of liver sphere formation, as well as the area of the
liver spheres, which might be also due to the galunisertib-
mediated inhibition of cell proliferation.
Galunisertib reduces the invasive growth capacity of HCC
cells
The three-dimensional (3-D) tumor spheroid invasion
assay is a vastly robust technique used to form 3-D
spheroids using the hanging drop technique. To evaluate
the effect of galunisertib on the functionality of the
invasive HCC cells (HLE and HLF), we pretreated the cells
for 48 h in the presence or absence (control, dimethyl
sulfoxide [DMSO]) of galunisertib. The generated 3-D
spheroids were embedded into the collagen I matrix to
allow the invasive growth of the cells. As reported in
Fig. 5, galunisertib decreased the invasive capacity of HLE
and HLF cells respect to controls.
Stable knockdown of CD44 mimicked the effects of
galunisertib on HCC stemness properties
To explain galunisertib effectiveness on HCC cell
stemness and invasiveness we tested the hypothesis
that the modulation of CD44 expression mediates such
effects. We induced CD44 knockdown in HLE cells
through shRNA. The capacity to form colonies at low
dilutions in the HLEshCD44 cells was significantly lower
than in control cells (Fig. 6a). HLEshCD44
cells also formed a lower number of liver spheroids as
compared to the HLEsh− controls (Fig. 6b). These results
indicate the relevance of CD44 expression on the
stemness-related functional properties of HCC cells.
Interestingly, when we analyzed the additional effect
of galunisertib on these properties in HLEshCD44 cells,
we observed a further reduction in their clonogenic
capacity, but barely effect on the ability of cells to form
spheroid, when compared with the corresponding
untreated HLEshCD44 cells, suggesting that the decrease
in CD44 expression may be the main molecular
mechanism undergone by galunisertib to reduce spheroid
formation capacity of the HCC cells. Knockdown of CD44
also produced a decrease in the invasive ability of
HLE cells (Fig. 7), similar to galunisertib treatment.
In parallel to the results observed on the stemness-related
properties, treatment of galunisertib in HLEshCD44
cells showed only a slight additional effects on their
invasive capacity. Altogether, these results indicate that
targeting knockdown of CD44 mimicked most of the
effects of galunisertib on CSCs and invasive properties in
HLE cells.
Fig. 3 Effect of stable TGFβR1 knockdown on mesenchymal stemness-related gene expression in invasive HCC cells. a Relative expression of
CD44 and THY1 genes analyzed by qRT-PCR. b Flow cytometry analysis of CD44 and THY1 markers expressed on the cell surface. Results are expressed
as MFI. Mean ± SEM (N at least 3). *P < 0.05; **P < 0.001
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Fig. 4 Galunisertib reduces clonogenicity and liver spheroid formation ability of HCC invasive cells. a Colony formation assay. After
galunisertib treatment, HLE (left panel) and HLF (right panel) cells were serially diluted into 500, 200, and 100 cells and cultured for 12 days. Data
represent quantification of the number of colonies per well. b Ability of growing in spheroids in the absence of attachment. The % of wells with
spheroids during first, second, and third cell generation is shown. c Variation on the area of liver spheroids during first, second, and third cell
generation is shown. Mean ± SEM (N at least 3). *P < 0.05; **P < 0.001; ***P < 0.0001
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Galunisertib reduces the expression of stemness-related
genes in ex vivo HCC patients’ samples
To investigate the relevance in vivo, we quantified the
expression of TGFβ1 and stemness-related genes follow-
ing treatment with galunisertib in ex vivo tumor samples
from 24 HCC patients. Tumor samples were categorized
as responders (13) and non-responders (11), based on
TGFβ1 expression after galunisertib treatment in ex vivo
experimental model. In the responders cohort, galuni-
sertib treatment reduced the expression of CD44 and
THY1 genes as compared to the controls (Fig. 8). These
results suggest that TGFβ1 expression in HCC patients
might play a significant role in maintaining CSC niche
during HCC and, subsequently, the aggressiveness of this
malignancy, while galunisertib is effectively reducing the
stemness-related gene expression in HCC patients’ sam-
ples. These data support our in vitro findings and might
serve as a strong evidence of galunisertib use as a potential
targeted therapy against HCC.
Discussion
Herein, we studied a panel of staminal biomarkers in
seven different epithelial and mesenchymal HCC cell lines
with different epithelial–mesenchymal characteristics and
different response to TGF-β as suppressor or pro-
tumorigenic17–19. Our results indicate that HCC cells
exhibited a distinctive profile of stemness-related genes
according to their TGF-β-dependent signature: early
(epithelial, responding to the suppressor effects of TGF-β)
or late (mesenchymal with autocrine production of TGF-β
and unresponsive to its suppressor effects). In particular,
the non-invasive, epithelial “early” TGF-β signature HCC
cells express EPCAM, ANPEP, KRT19 and PROM1,
whereas the invasive, mesenchymal “late” TGF-β
Fig. 5 Galunisertib reduces the invasive growth capacity of HCC cells. Invasive growth assay in 3-D culture. Representative images of spheroids
obtained with HLE (a) and HLF (b) cells are shown in the left panel. The quantification of invasive growth capacity show (right panel) was calculated
as the increase of the area occupied by the spheroids between day 0 and day 4. The line in the dot-plot graph represents mean value
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signature HCC cells express CD44 and THY1. Endothelial
SK-HEP-1 cells express ANPEP, previously described as a
marker of monocytes and endothelial cells20. Our study
differs from others, since we examined a broad panel of
stemness-related genes in various invasive and non-
invasive HCC cells. TGF-β has been recently reported to
act as a mediator of the mesenchymal phenotype observed
in some HCC cell lines18,21 and HCC tissues22, which
bestows these cells with a higher migratory and invasive
capabilities and apoptosis resistance. In our study, the
knockdown of TGFβRI in HLE and HLF cells reduces the
expression of mesenchymal markers, in particular, CD44
and THY1, both at mRNA and protein levels. Knockdown
of TGFβRI exerts similar effects as observed by inhibiting
TGFβRI with its specific inhibitor galunisertib. We found
that galunisertib reduces the expression of CD44 and
THY1 in HLE and HLF cells at both mRNA and protein
levels. Altogether, these results indicate that TGF-β
mediates the expression of CD44 and THY1 in invasive
HCC cells. CD44 is a cell surface glycoprotein that
functions as a receptor for hyaluronic acid23, is involved in
cell–cell adhesion and migration, and has been showed to
be associated with tumor cell invasion and migration in
liver cancer24,25. We recently found that when TGF-β
induces EMT in HCC cells, a switch in the expression of
stemness-related genes is observed, concomitant with up-
regulation of CD44, and their stemness potential and
migratory/invasive capacity are enhanced26,27. Here we
show that galunisertib reduces the expression of CD44,
affecting the ability of invasive HCC cells to form colo-
nies, liver spheroids, and 3-D invasion. Moreover, galu-
nisertib exhibited anti-proliferative activity in ex vivo
models representing a more physiological model, sig-
nifying that inhibition of TGF-β can exert anti-tumoral
Fig. 6 Stable knockdown of CD44 mimicked the effects of galunisertib on HCC stemness properties. a Colony formation assay. After
galunisertib treatment, HLEsh− and HLEshCD44 cells were serially diluted into 500, 200, and 100 cells and cultured for 12 days. Data represent
quantification of the number of colonies per well. Flow cytometry analyses of CD44 expressed on the cell surface are shown (right panel). Results are
expressed as MFI. b Ability to grow in spheroids in the absence of attachment. The % of wells with spheroids during first, second and third cell
generation is shown. Mean ± SEM (N at least 3). *P < 0.05; **P < 0.001; ***P < 0.0001
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effects, which might be mediated by the tumor
microenvironment28,29. Its use under clinical phase II trial
study (Eli Lilly) is allowing the design of a road map for
personalizing cancer therapy in HCC by using molecular
pattern diagnostics30. This is an important first evidence-
based study presented the efficacy of galunisertib treat-
ment in HCC, where it modulates the expression of
stemness genes and hence providing the proof to support
its use in currently ongoing clinical trials.
Recent evidence has reported that CD44 promotes
tumor invasion and metastasis in multiple cancer types
including colon, prostate, bladder, breast, and liver can-
cers31–33. The proposed mechanism is that CD44 inhibits
the membrane-located E-cadherin and β-catenin, result-
ing in nuclear translocation of β-catenin and transcrip-
tional activation of genes related to cell invasion and
migration32,33. This is consistent with our new findings,
where the silencing of CD44 inhibits the colony forma-
tion, liver spheroids formation and maintenance, as well
as invasive growth ability in HLE cells, indicating the
potential role of CD44 in liver pathogenesis. The
attenuation or even loss in the response to galunisertib in
CD44 knockdown cells indicate that down-regulation of
CD44 by galunisertib may be one of the relevant
mechanisms undergone by this drug to mediate its effects
on stemness and invasion in HCC cells.
Our ex vivo assays of human HCC patient samples
supports the in vitro data. TGFβ1 signatures were differ-
ent in different HCC samples before or after treatment
with galunisertib. The expression of CD44 and THY1
were reduced in responders as compared to the non-
responders. Previous research has already shown that
TGF-β is upregulated in HCC and plays an important role
in the HCC progression. Also, it has been indicated that
CD44s plays a critical role in the TGF-β-mediated
mesenchymal phenotype and is associated with poor
prognosis of HCC patients25 and also that THY1 and
CD44 act as a potential biomarker for HCC34. Moreover,
our data emphasized the potential use of galunisertib-
mediated regression of HCC, particularly, to decrease the
expression of stemness genes and associated decrease of
stemness-related abilities.
In summary, we have shown for the first time the effect
of galunisertib on the expression of stemness genes in
HCC. Our study strongly supports the promising bene-
ficial use of galunisertib clinically, as this drug reduces the
clonogenic capacity, liver spheroid formation, and inva-
sive ability of HCC cells in vitro. Furthermore, our results
extend previous data indicating that CD44 might be under
the control of TGFβ1 signaling, contributing to the more
aggressive phenotype of HCC. Knocking down of CD44
proved the essential role of CD44 in the formation of
colonies, liver spheroid, and invasive ability in vitro,
mimicking the results obtained from the inhibition of
TGFβ1 by galunisertib, where the drug reduced the
expression of CD44 and hence decreased the functionality
of HCC cells. Our in vitro data are supported by the
ex vivo study on HCC patient samples, where we have
shown that galunisertib effectively reduces the expression
of TGFβ1 in responders, but not in non-responder
patients. Moreover, we have shown that galunisertib
efficiently reduced the expression of stemness genes in
responders. These experimental studies would be relevant
in accessing the efficacy of the galunisertib treatment, in
order to improve therapeutic and management decisions
in personalized medicine.
Material and methods
Cell lines and culture conditions
HepG2, PLC/PRF/5, Hep3B, SK-HEP-1 and SNU449
cells were obtained from ATCC (Manassas, VA, USA).
Fig. 7 Targeting knockdown of CD44 mimicked the effects of
galunisertib on invasive properties of HCC cells. a Invasive growth
assay in 3-D culture. Representative images of spheroids are shown. b
Quantification of invasive growth capacity in 3-D culture. The increase
of the area occupied by the spheroids between day 0 and day 4 was
calculated. The line in the dot-plot graph represents mean value.
*P < 0.05; **P < 0.001; ***P < 0.0001
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HLE and HLF cells were from the Japanese Collection of
Research Bioresources Cell Bank (JCRB Cell Bank, Japan).
Cell lines were never used in the laboratory for longer
than four months after receipt or resuscitation. Myco-
plasma contamination was excluded in all the results
presented in the manuscript. HepG2, PLC/PRF/5, Hep3B,
and SK-HEP-1 cells were cultured in Dulbecco’s modified
Eagle's medium (DMEM) with 4.5 g/L D-glucose. HLE,
HLF, and SNU449 cells were cultured in Roswell Park
Memorial Institute (RPMI) 1640 medium with
L-glutamine, Phenol red. Both supplemented with 10%
heat-inactivated fetal bovine serum (FBS) from Gibco®
(Life Technologies™, Paisley, UK), penicillin (100 U/mL),
streptomycin (100 μg/mL), and sodium bicarbonate (1.5
g/L). Trypsin 0.05%-EDTA 0.02% with Phenol red
was purchased from EuroClone (Italy) and 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid) HEPES (20 nm)
from Gibco®. Methyl cellulose and collagen IV solution
were from Sigma-Aldrich (St. Louis, MO, USA). Matrigel
matrix was from Corning (NY, USA). Cells were
maintained at 37 °C in a humidified atmosphere and
5% CO2.
Analysis of gene expression
A total of 100 ng RNA of HCC cell lines and 1 µg RNA
from Human HCC tissues were used for first-strand
complementary DNA (cDNA) synthesis for gene expres-
sion analysis. RT-PCR amplification was performed using
CFX96 Real-Time system (C1000 Thermal cycler)
(BioRad). Data were analyzed according to the delta-delta
Ct method. Triplicate wells and biological triplicates were
analyzed in each assay. Glyceraldehyde 3-phosphate
dehydrogenase gene (GAPDH) was used as endogenous
control. The following primers were obtained from Inte-
grated DNA Technologies® (Leuven, Belgium):
TGFβ1
Forward: 5′-CCG AGA AGC GGT ACC TGA AC-3′.
Reverse: 5′-GAG GTA TCG CCA GGA ATT GTT
G-3′.
EPCAM
Forward: 5′-TCC AGA ACA ATG ATG GGC TTT-3′.
Reverse: 5′-TTG CAC TGC TTG GCC TTA AA-3′.
Fig. 8 Galunisertib reduces the expression of stemness-related genes in ex vivo HCC patients’ samples. a Relative expression of TGFβ1
analyzed by qRT-PCR following treatment with galunisertib in ex vivo tumor samples from HCC patients. b Relative expression of CD44 and THY1
analyzed by qRT-PCR. Mean ± SEM (number of patients= 24, each experiment technically performed in triplicate). *P < 0.05; **P < 0.001
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PROM1
Forward: 5′-ACA GCG ATC AAG GAG ACC AAA-3′.
Reverse: 5′-TTT GTT GGT GCA AGC TCT TCA-3′.
CD44
Forward: 5′-TGG AGA AAA ATG GTC GCT ACA G-
3′.
Reverse: 5′-GGG CAA GGT GCT ATT GAA AGC-3′.
THY1
Forward: 5′-ACC TCT TCC TCT TCC CTG ACT TC-
3′.
Reverse: 5′-GCC CAG TGT GCA GTC ATT AGC-3′.
ANPEP
Forward: 5′-CCG TCT ACT GCA ACG CTA TCG-3′.
Reverse: 5′-ATT GAC CAG TGT GGC ATT TCG-3′.
KRT19
Forward: 5′-AGG TCA GTG TGG AGG TGG ATT C-
3′.
Reverse: 5′-GCT TCG CAT GTC ACT CAG GA-3′.
GAPDH
Forward: 5′-CAC CAT CTT CCA GGA GCG AG-3′.
Reverse: 5′-GAC TCC ACG ACG TAC TCA GC-3′.
Drug assay
Respective cells were treated either with control
(DMSO), 5 ng/mL of recombinant human TGFβ1
(PeproTech, Germany) or galunisertib (10 µM) (Eli Lilly
and Company, Indianapolis, IN, USA), and in combina-
tion of TGFβ1+ galunisertib. On the other hand, invasive
HCC cell lines were treated with 10 µM of galunisertib
and control (DMSO). RNA was isolated after 48 h of
respective treatments and gene expression was analyzed
by qRT-PCR. Triplicate wells and biological triplicates
were analyzed in each assay.
Flow cytometry
Procedure was carried out as described previously27.
A total of 1 × 106 cells were incubated in FACS buffer
(FBS+ 0.1% bovine serum albumin) and respective
fluorescence-conjugated antibodies. Flow cytometry was
performed using Beckman Coulter Counter analyzer
(Beckman and Coulter) and analysis was performed using
Kaluza analysis software (Beckman and Coulter).
Western blotting
Procedure was carried out as described previously18.
Total protein extracts were obtained using a lysis buffer
containing 30 mM Tris–HCl pH 7.5, 5 mM EDTA, 150
mM NaCl, 1% Triton X-100, 0.5% sodium deoxycolate,
0.1% SDS, and 10% glycerol (1 h at 4 °C; centrifugation at
13,000 rpm, 10 min, 4 °C). Protein concentration was
measured with the BCA Protein Assay kit (Pierce). β-
ACTIN is shown as a loading control. Antibodies were
used at a 1:1000 dilution, except for β-ACTIN (1:3000).
Images were processed with Adobe Photoshop CS5.
Colony formation assay
Procedure was carried out as described previously27.
Colony assay was performed to determine the ability of a
“single cell” to grow into a “colony”. Cells were serially
diluted into 500, 200, 100 cells and cultured in six-well
plates for 12 days. Fresh pulse of galunisertib was given
every third day, until the end of the experiment. Upon
termination of the assay, the colonies were stained with
crystal violet (0.2% in 2% ethanol) and colonies, which
consist of at least 50 cells, were scored and counted using
a stereomicroscope. The number of colonies was calcu-
lated using ImageJ software.
Invasive growth assay
Procedure was carried out as described previously27.
Cells were resuspended in low viscosity media in a con-
centration of 4 × 105 cells/mL and suspended as hanging
drops for 72 h at 37 °C–5% CO2, to allow them to cluster
into compact sphere-like formation. Post 72 h, spheroids
were embedded into Pure Col® Type I Bovine collagen
solution (3 mg/mL) (1.7 mg/mL in DMEM) and incubated
in the presence of 10 µM of galunisertib added to 10%
FBS-containing media at 37 °C–10% CO2. Phase contrast
pictures were taken every 24 h, during 4 days. On second
and fourth day, fresh pulse of medium containing 10 µM
of galunisertib were added to each respective well. For
quantification, increase of the area occupied by the
spheroids between day 0 and day 4 was calculated using
ImageJ software.
Analysis of spheroid formation capacity under anchorage-
independent conditions
Cells were seeded as hanging drop (1000 cells/drop) in
aGravityPLUS™ plate. Tumor spheroids of the first gen-
eration were transferred into InSphero GravityTRAP™
plates and the number of spheroids per plate was counted
under microscope. Spheres were later dissociated into
single cell suspensions and serially passaged under the
same initial culture conditions. The percentage of wells
with spheroids counted during every generation.
Ethical approval, HCC patients’ sample, collection, and
ex vivo assays
Approval for the human HCC patient study was
obtained from the local Ethics Committee of the Azienda
Ospedaliero-Universitaria Policlinico, Bari (Apulia), Italy.
Patients were given prior written informed consent to the
use of their tissues. This study was performed in
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accordance with the Helsinki Declaration and informed
written consent was obtained from all patients. Addi-
tionally, the data were analyzed anonymously. Surgical
samples were obtained during HCC patient surgery at
Policlinico, Bari, Italy. Twenty-four HCC tissues were
processed into three parts and processed for routine
histology, snap-frozen in liquid nitrogen and for the
ex vivo study. The tumor tissue was processed into 2 mm
size and cultured for 48 h in Iscove’s modified Dulbecco’s
medium supplemented with 20% FBS. After 48 h, the
tissues were snap- frozen and later RNA was isolated from
the frozen HCC tissue. RNA was quantified and tran-
scribed into cDNA and stemness-related gene expression
was analyzed by qRT-PCR. Patient samples were classified
as responders and non-responders based on their endo-
genous TGF-β expression level, which is compared with
control conditions (without galunisertib).
Targeted knockdown assays
Four different shRNA plasmids for TGFβRI and two for
CD44 as well as unspecific shRNA were kindly provided
by Isabel Fabregat. Cells selected for the experiments are
those where maximal knockdown of TGFβ was observed,
as previously described26,27.
Statistical analyses
Statistical analyses for all experiments were performed
using two-tailed Student t-test and statistical significance
was set at a P-value of <0.05. All data represent at least
three experiments and are expressed as the mean ± stan-
dard error of the mean (SEM).
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